Logo image of NNVC

NANOVIRICIDES INC (NNVC) Stock Fundamental Analysis

NYSEARCA:NNVC - American Stock Exchange - US6300873022 - Common Stock - Currency: USD

1.3  +0.16 (+14.04%)

After market: 1.28 -0.02 (-1.54%)

Fundamental Rating

2

Overall NNVC gets a fundamental rating of 2 out of 10. We evaluated NNVC against 572 industry peers in the Biotechnology industry. NNVC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NNVC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NNVC had negative earnings in the past year.
NNVC had a negative operating cash flow in the past year.
NNVC had negative earnings in each of the past 5 years.
NNVC had a negative operating cash flow in each of the past 5 years.
NNVC Yearly Net Income VS EBIT VS OCF VS FCFNNVC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -80.51%, NNVC is doing worse than 69.20% of the companies in the same industry.
NNVC has a Return On Equity (-93.51%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -80.51%
ROE -93.51%
ROIC N/A
ROA(3y)-38.17%
ROA(5y)-46.67%
ROE(3y)-40.8%
ROE(5y)-52.73%
ROIC(3y)N/A
ROIC(5y)N/A
NNVC Yearly ROA, ROE, ROICNNVC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NNVC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NNVC Yearly Profit, Operating, Gross MarginsNNVC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, NNVC has more shares outstanding
NNVC has more shares outstanding than it did 5 years ago.
There is no outstanding debt for NNVC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NNVC Yearly Shares OutstandingNNVC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
NNVC Yearly Total Debt VS Total AssetsNNVC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -13.45, we must say that NNVC is in the distress zone and has some risk of bankruptcy.
NNVC's Altman-Z score of -13.45 is on the low side compared to the rest of the industry. NNVC is outperformed by 80.53% of its industry peers.
There is no outstanding debt for NNVC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.45
ROIC/WACCN/A
WACCN/A
NNVC Yearly LT Debt VS Equity VS FCFNNVC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 2.48 indicates that NNVC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.48, NNVC is doing worse than 71.68% of the companies in the same industry.
A Quick Ratio of 2.48 indicates that NNVC has no problem at all paying its short term obligations.
NNVC has a worse Quick ratio (2.48) than 70.62% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 2.48
NNVC Yearly Current Assets VS Current LiabilitesNNVC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.83% over the past year.
EPS 1Y (TTM)2.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NNVC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.12% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-12.5%
EPS Next 2Y-22.47%
EPS Next 3Y1.64%
EPS Next 5Y8.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NNVC Yearly Revenue VS EstimatesNNVC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
NNVC Yearly EPS VS EstimatesNNVC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NNVC. In the last year negative earnings were reported.
Also next year NNVC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NNVC Price Earnings VS Forward Price EarningsNNVC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NNVC Per share dataNNVC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.47%
EPS Next 3Y1.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NNVC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANOVIRICIDES INC

NYSEARCA:NNVC (2/5/2025, 8:17:14 PM)

After market: 1.28 -0.02 (-1.54%)

1.3

+0.16 (+14.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)02-12 2025-02-12
Inst Owners9.18%
Inst Owner Change-0.45%
Ins Owners0.66%
Ins Owner Change0%
Market Cap18.66M
Analysts82.86
Price Target6.63 (410%)
Short Float %1.33%
Short Ratio0.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.85
P/tB 1.91
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0
BVpS0.7
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -80.51%
ROE -93.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.17%
ROA(5y)-46.67%
ROE(3y)-40.8%
ROE(5y)-52.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.28%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 2.48
Altman-Z -13.45
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)32.55%
Cap/Depr(5y)21.81%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.1%
EPS Next Y-12.5%
EPS Next 2Y-22.47%
EPS Next 3Y1.64%
EPS Next 5Y8.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-14.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.7%
OCF growth 3YN/A
OCF growth 5YN/A